maklogo
Market Research Report

Global Biopharmaceutical Vaccines Market Insights, Size, and Forecast By Patient Age Group (Pediatric, Adult, Geriatric), By Disease Type (Infectious Diseases, Autoimmune Diseases, Cancer, Neurological Disorders), By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines), By Route of Administration (Subcutaneous, Intramuscular, Intradermal, Oral), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:90013
Published Date:Jan 2026
No. of Pages:228
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Biopharmaceutical Vaccines Market is projected to grow from USD 78.5 Billion in 2025 to USD 155.2 Billion by 2035, reflecting a compound annual growth rate of 8.7% from 2026 through 2035. This robust growth underscores the critical role of biopharmaceutical vaccines in global public health, encompassing preventive and therapeutic applications against a wide spectrum of diseases. The market is propelled by several key drivers, including the increasing prevalence of infectious diseases, rising awareness about preventive healthcare, and significant advancements in vaccine technology, such as mRNA and viral vector platforms. Furthermore, government initiatives and funding for immunization programs, coupled with a growing elderly population more susceptible to infections, contribute significantly to market expansion. While the Infectious Diseases segment currently holds the dominant share, the continuous evolution of vaccine research promises diversification into other therapeutic areas. The market also observes an increasing trend towards combination vaccines and personalized vaccine approaches, driven by the desire for broader protection and enhanced efficacy. However, challenges such as high development costs, stringent regulatory approval processes, and public hesitancy towards vaccination act as notable restraints. Despite these hurdles, the market presents substantial opportunities in emerging economies, novel vaccine targets, and the integration of artificial intelligence and machine learning in vaccine discovery and development.

Global Biopharmaceutical Vaccines Market Value (USD Billion) Analysis, 2025-2035

maklogo
8.7%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

North America leads the global biopharmaceutical vaccines market, primarily due to well-established healthcare infrastructure, high healthcare expenditure, significant research and development investments, and the presence of major pharmaceutical and biotechnology companies. The region benefits from robust regulatory frameworks that facilitate vaccine development and commercialization, alongside strong public and private sector support for immunization programs. Conversely, Asia Pacific is poised to be the fastest growing region, driven by its large and underserved patient population, improving healthcare access, increasing government focus on preventive healthcare, and a growing number of local pharmaceutical manufacturers investing in vaccine production. The rising incidence of infectious diseases and expanding immunization coverage in countries like India and China are key factors fueling this rapid expansion. The market segmentation by Vaccine Type, Disease Type, Route of Administration, and Patient Age Group further illustrates the diverse landscape and the tailored approaches required for different therapeutic needs and demographic groups.

Key players in the biopharmaceutical vaccines market, including Novartis, Bayer, AbbVie, AstraZeneca, Takeda, Johnson & Johnson, Merck & Co, Pfizer, GSK, and Roche, are actively engaged in strategic initiatives to maintain and expand their market presence. These strategies often involve extensive research and development to introduce innovative vaccines, strategic mergers and acquisitions to broaden product portfolios and gain market share, and collaborations with academic institutions and biotechnology firms to leverage cutting-edge technologies. Additionally, companies are focusing on expanding their manufacturing capabilities and distribution networks, particularly in emerging markets, to address global demand and enhance accessibility. The emphasis on developing vaccines for unmet medical needs and improving vaccine efficacy and safety profiles remains a paramount objective for these industry leaders, solidifying the market’s trajectory towards continued innovation and growth.

Quick Stats

  • Market Size (2025):

    USD 78.5 Billion

  • Projected Market Size (2035):

    USD 155.2 Billion

  • Leading Segment:

    Infectious Diseases (89.4% Share)

  • Dominant Region (2025):

    North America (38.7% Share)

  • CAGR (2026-2035):

    8.7%

Global Biopharmaceutical Vaccines Market Emerging Trends and Insights

mRNA Beyond COVID New Vaccine Frontiers

mRNA technology, catapulted into prominence by COVID19 vaccines, is now expanding its revolutionary impact far beyond the pandemic. This trend signifies a substantial shift in vaccine development, leveraging mRNA's inherent flexibility and speed. Researchers are actively exploring mRNA platforms for a myriad of infectious diseases, including influenza, RSV, HIV, malaria, and even Lyme disease. The ability to rapidly design and manufacture new mRNA vaccine candidates, bypassing traditional lengthy cell culture processes, is a game changer. Furthermore, the technology shows immense promise in therapeutic applications like oncology, where it can stimulate the immune system to target cancer cells. This frontier involves delivering specific mRNA sequences to express antigens or other proteins, driving targeted immune responses against a broader spectrum of health threats.

AI Driven Vaccine Design Accelerated Development

AI is revolutionizing vaccine development by dramatically shortening discovery and design phases. Traditionally, identifying promising antigen targets and designing effective vaccine constructs was a lengthy, laborious process. Now, artificial intelligence algorithms analyze vast biological datasets, including pathogen genomics and host immune responses, with unparalleled speed and accuracy. This allows AI to predict optimal antigen candidates, design novel vaccine platforms, and even engineer specific epitopes to elicit robust and durable immunity. Machine learning models can also accelerate lead optimization by simulating molecular interactions and predicting efficacy and safety profiles in silico. This AI driven approach bypasses much of the trial and error in early development, leading to a significant acceleration in bringing new, highly effective vaccines from concept to clinical trials, thereby transforming the global biopharmaceutical vaccines landscape.

Personalized Vaccines Tailored Immunization Approaches

The Global Biopharmaceutical Vaccines Market is witnessing a significant trend towards personalized vaccines and tailored immunization approaches. This shift reflects a move beyond traditional one size fits all vaccine strategies. Instead researchers are developing vaccines designed to elicit specific immune responses in individuals based on their unique genetic makeup health status and previous exposures. Technologies like genomics proteomics and advanced immunological profiling enable the identification of specific antigens or epitopes that are most effective for an individual. This precision medicine approach aims to optimize vaccine efficacy reduce potential side effects and broaden the scope of preventable diseases especially in areas like cancer immunotherapy and chronic infectious diseases where conventional vaccines may be less effective for diverse populations. It signifies a future of highly individualized and more effective preventative medicine.

What are the Key Drivers Shaping the Global Biopharmaceutical Vaccines Market

Rising Incidence of Infectious Diseases & Pandemic Preparedness

The growing frequency and spread of infectious diseases worldwide are a critical driver for the global biopharmaceutical vaccines market. Pathogens like novel viruses and antibiotic-resistant bacteria constantly emerge, posing significant public health threats. These outbreaks, ranging from regional epidemics to global pandemics, necessitate rapid development and deployment of new vaccines. Governments and healthcare organizations are increasingly investing in research and development to enhance preparedness for future health crises. This proactive approach includes funding for innovative vaccine platforms, accelerated regulatory pathways, and expanded manufacturing capabilities to ensure timely access to effective prophylactic solutions. The continuous threat of new infections and the imperative for swift responses are fueling sustained demand for novel and improved vaccines.

Accelerated Vaccine R&D and Technological Advancements

Rapid progress in vaccine research and development is a key driver. Innovations in platform technologies like mRNA and viral vectors have revolutionized the speed and scalability of vaccine production. These advancements enable faster identification of promising vaccine candidates and accelerate their progression through clinical trials. Furthermore, enhanced understanding of immunology and pathogen biology contributes to the development of more effective and broader spectrum vaccines. The integration of artificial intelligence and machine learning is streamlining discovery processes and optimizing vaccine design. These technological leaps allow for quicker responses to emerging infectious diseases and continuous improvement in existing vaccine formulations, ensuring a robust pipeline of new and improved vaccines reaching patients globally.

Expanding Immunization Programs & Public Health Initiatives

Expanding immunization programs and public health initiatives are a key growth driver for the global biopharmaceutical vaccines market. Governments and international organizations are increasingly recognizing the crucial role of vaccination in preventing disease outbreaks and safeguarding population health. This heightened awareness translates into substantial investments in establishing and strengthening national immunization programs, particularly in low and middle income countries. These initiatives focus on improving vaccine access, addressing hesitancy through educational campaigns, and expanding the range of diseases covered by routine immunization schedules. Furthermore, new public health drives targeting specific regions or demographic groups for specific diseases also necessitate increased vaccine production and distribution, thereby fueling market expansion.

Global Biopharmaceutical Vaccines Market Restraints

Vaccine Hesitancy and Misinformation Spread

Vaccine hesitancy and misinformation significantly impede growth within the global biopharmaceutical vaccines market. Public apprehension fueled by unsubstantiated claims regarding vaccine safety and efficacy directly reduces uptake rates. False narratives spread through social media and other channels create distrust in scientific consensus and public health authorities. This skepticism translates into lower vaccination coverage for both existing and newly developed vaccines impacting their market penetration. Companies face the challenge of overcoming deeply entrenched beliefs and combating the rapid dissemination of false information. This resistance to vaccination not only slows market expansion but also necessitates substantial investment in public education campaigns and efforts to counter misinformation directly affecting the commercial success of vaccine manufacturers.

Stringent Regulatory Hurdles and Lengthy Approval Processes

Developing and introducing new biopharmaceutical vaccines faces significant obstacles due to stringent regulatory hurdles and lengthy approval processes. Vaccine candidates must undergo rigorous preclinical testing and multiple phases of clinical trials to demonstrate safety and efficacy. These trials often span several years and involve large patient populations, generating extensive data for review. Regulatory bodies worldwide, such as the FDA and EMA, maintain high standards for vaccine approval, necessitating meticulous documentation, quality control, and manufacturing compliance. The extensive review periods for these submissions further prolong market entry. This comprehensive and time consuming process, while crucial for public health and safety, significantly extends the development timeline and increases the financial burden on pharmaceutical companies, effectively limiting the speed at which innovative vaccines can reach the global market.

Global Biopharmaceutical Vaccines Market Opportunities

mRNA and AI Synergies: Pioneering Rapid-Response Vaccines for Emerging Pathogens and Therapeutic Applications

The convergence of messenger RNA technology and artificial intelligence represents a transformative opportunity within the global biopharmaceutical vaccines market. This powerful synergy enables the expedited design and development of novel vaccines to combat unforeseen emerging pathogens with unprecedented speed. AI algorithms can rapidly analyze vast biological datasets, predict viral mutations, optimize antigen selection, and significantly accelerate preclinical stages, drastically reducing traditional vaccine development timelines. mRNA platforms, known for their inherent flexibility and rapid manufacturing capabilities, then facilitate swift and scalable production. Beyond prophylactic measures, this innovative approach extends into therapeutic applications, unlocking new frontiers in precision medicine for challenging conditions like cancer or autoimmune disorders. The ability to rapidly respond to global health crises and pioneer new treatment modalities positions stakeholders at the forefront of medical innovation, addressing critical unmet needs and capturing substantial value in a dynamic and evolving market. This integration marks a paradigm shift in vaccine science and healthcare delivery.

Beyond Pediatric: Developing Lifecycle Vaccines for Adult Immunization and Therapeutic Cancer Applications

The global biopharmaceutical vaccines market presents a compelling opportunity by expanding its focus significantly beyond traditional pediatric immunization. This involves developing comprehensive lifecycle vaccines specifically tailored for adult immunization. Addressing a vast and often underserved population, these innovations will target prevalent adult infectious diseases like influenza, RSV, and shingles, alongside emerging pathogens. This strategic pivot ensures lifelong immune protection, moving beyond childhood disease prevention to sustained health across all adult stages. A particularly transformative frontier lies in therapeutic cancer applications, where vaccines are engineered to stimulate the body's immune system to actively fight existing cancers. This novel treatment modality presents immense potential for oncology. This dual emphasis on proactive adult health and groundbreaking cancer therapy represents a profound market expansion. It unlocks substantial growth by applying advanced vaccine science to address critical unmet medical needs throughout the human lifespan, revolutionizing both preventative care and disease intervention.

Global Biopharmaceutical Vaccines Market Segmentation Analysis

Key Market Segments

By Vaccine Type

  • •Live Attenuated Vaccines
  • •Inactivated Vaccines
  • •Subunit Vaccines
  • •mRNA Vaccines
  • •Viral Vector Vaccines

By Disease Type

  • •Infectious Diseases
  • •Autoimmune Diseases
  • •Cancer
  • •Neurological Disorders

By Route of Administration

  • •Subcutaneous
  • •Intramuscular
  • •Intradermal
  • •Oral

By Patient Age Group

  • •Pediatric
  • •Adult
  • •Geriatric

Segment Share By Vaccine Type

Share, By Vaccine Type, 2025 (%)

  • mRNA Vaccines
  • Subunit Vaccines
  • Inactivated Vaccines
  • Viral Vector Vaccines
  • Live Attenuated Vaccines
maklogo
$78.5BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is Disease Type a crucial segmentation variable, with infectious diseases holding a dominant share?

Infectious diseases overwhelmingly dominate the biopharmaceutical vaccines market, capturing nearly 90 percent of the share. This dominance stems from the historical foundation of vaccinology, which primarily focused on preventing widespread and often deadly infectious pathogens like influenza, polio, measles, and tetanus. Extensive global immunization programs, established infrastructure for distribution, and continuous research against emerging and re-emerging infectious threats solidify this segment's leading position. While therapeutic vaccines for other disease areas are gaining traction, the preventative nature and broad public health impact of infectious disease vaccines drive their unparalleled market presence.

How do advancements in vaccine technology influence the segmentation by Vaccine Type?

The segmentation by vaccine type is dynamically shifting with rapid technological advancements. Traditionally, live attenuated and inactivated vaccines formed the backbone of the market. However, the emergence of subunit, viral vector, and especially mRNA vaccine platforms signifies a major evolutionary leap. These newer technologies offer advantages such as faster development timelines, enhanced specificity, and adaptability, not only improving existing infectious disease vaccines but also unlocking potential for therapeutic applications in areas like cancer and autoimmune conditions. This evolution creates a more diverse vaccine type landscape, promising greater efficacy and broader application scope.

What impact does Patient Age Group have on vaccine development and market segmentation?

Patient age group significantly influences vaccine development and market segmentation due to varying immune responses and disease susceptibilities across different life stages. Pediatric populations have distinct immunization schedules to protect against childhood diseases and support immune system development. Adults require boosters and vaccines for specific risks, while geriatric populations often need vaccines tailored for immunosenescence and increased vulnerability to infections like influenza and shingles. This necessitates specific formulations, dosages, and administration routes for each age group, driving differentiated product portfolios and targeted public health strategies across the pediatric, adult, and geriatric segments.

Global Biopharmaceutical Vaccines Market Regulatory and Policy Environment Analysis

The global biopharmaceutical vaccines market navigates an exceptionally stringent and dynamic regulatory environment. National health authorities, such as the FDA, EMA, and PMDA, enforce rigorous multi phase clinical trials and extensive pre market authorization. Post market surveillance and pharmacovigilance are critical for ongoing safety and efficacy monitoring. International harmonization efforts, led by the WHO and ICH, aim to streamline development and approval, although significant regional variations persist. Expedited review pathways have emerged for urgent public health needs, particularly evident during recent pandemics.

Policy frameworks strongly influence market access, pricing, and reimbursement. Governments worldwide prioritize immunization programs, often subsidizing vaccines and mandating specific schedules. Health technology assessments frequently determine market entry and pricing. Furthermore, manufacturing standards, including Good Manufacturing Practices, are strictly enforced globally, alongside robust supply chain integrity and cold chain requirements. Intellectual property protection and data exclusivity policies also shape innovation and investment in this vital sector. Equitable access and addressing vaccine hesitancy remain central policy challenges.

Which Emerging Technologies Are Driving New Trends in the Market?

The global biopharmaceutical vaccines market is experiencing transformative innovation. mRNA technology and advanced viral vector platforms are revolutionizing development, enabling rapid responses to emergent pathogens and significantly shortening timelines. Next generation protein subunit vaccines, bolstered by novel adjuvant systems, are enhancing immunogenicity and broadening protection against complex diseases.

Emerging technologies are further reshaping the landscape. Artificial intelligence and machine learning are powerfully applied in novel antigen discovery and vaccine design, promising more effective and cross protective candidates. Synthetic biology is poised to transform manufacturing processes, allowing for faster, more scalable production essential for pandemic preparedness. Personalized vaccine approaches targeting specific cancer types or chronic infections represent a future frontier. Furthermore, advancements in mucosal and needle free delivery systems aim to improve patient compliance and global accessibility, driving sustained market expansion and better public health outcomes.

Global Biopharmaceutical Vaccines Market Regional Analysis

Global Biopharmaceutical Vaccines Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
38.7%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 38.7% share

North America dominates the global biopharmaceutical vaccines market with a substantial 38.7% share. This leadership is driven by a robust research and development ecosystem, significant investment in biotechnology, and sophisticated healthcare infrastructure. The region benefits from strong government support for vaccine initiatives and the presence of numerous major pharmaceutical companies. High healthcare expenditure and a proactive approach to public health further solidify North America’s position. Advanced manufacturing capabilities and a well established regulatory framework also contribute to its prominent role in vaccine development and production, ensuring rapid innovation and widespread access to new vaccines.

Fastest Growing Region

Asia Pacific · 11.2% CAGR

Asia Pacific stands out as the fastest growing region in the global biopharmaceutical vaccines market, projected to achieve an impressive CAGR of 11.2% during the 2026-2035 forecast period. This rapid expansion is fueled by several converging factors. Increasing healthcare expenditure across emerging economies is a significant driver, enabling greater access to advanced medical treatments. A burgeoning patient population coupled with a rising prevalence of infectious diseases further escalates demand for effective vaccines. Furthermore, governments and private organizations in the region are actively investing in enhancing their vaccination programs and expanding public health infrastructure. The growing presence of local and international biopharmaceutical companies establishing manufacturing and research facilities within Asia Pacific also contributes significantly to this accelerated growth trajectory. This synergistic combination of factors positions Asia Pacific at the forefront of the global biopharmaceutical vaccines market expansion.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical tensions influence vaccine supply chains, impacting manufacturing and distribution. Nationalistic policies, like export restrictions and preferential procurement, disrupt global equity of access, creating disparities and potentially fostering parallel markets. Geopolitical alliances and rivalries affect collaborative research and development efforts, with some nations prioritizing domestic vaccine production over international partnerships, potentially slowing new variant responses. Intellectual property disputes among nations also complicate technology transfer and wider availability.

Macroeconomic conditions significantly shape vaccine accessibility and innovation. Inflation, particularly in raw materials and logistics, increases production costs, potentially leading to higher prices or reduced availability in low income countries. Economic growth in emerging markets could stimulate local production capabilities, fostering regional self sufficiency. However, recessionary pressures could reduce public health budgets, impacting vaccine procurement and distribution programs globally. Government funding for R&D, influenced by economic cycles, remains crucial for developing novel vaccines and addressing future pandemic threats.

Recent Developments

  • March 2025

    Pfizer and BioNTech announced a strategic partnership to develop next-generation mRNA vaccines targeting multiple respiratory viruses, including influenza and RSV. This collaboration aims to leverage their combined expertise in mRNA technology to create more effective and broadly protective vaccines for global markets.

  • February 2025

    GSK completed its acquisition of Affinivax, a clinical-stage biotechnology company focused on novel vaccine technologies. This acquisition strengthens GSK's vaccine pipeline with Affinivax's Multiple Antigen Presenting System (MAPS) technology, which holds promise for developing vaccines against a range of bacterial infections.

  • January 2025

    Moderna launched its updated mRNA-based influenza vaccine, mRNA-1010, after receiving accelerated approval in several key regions. This product launch marks Moderna's expansion beyond COVID-19 into the broader seasonal flu vaccine market, offering a novel approach to influenza prevention.

  • April 2025

    Merck & Co. announced a significant investment in expanding its vaccine manufacturing capabilities across multiple global sites. This strategic initiative aims to increase production capacity for its established vaccine portfolio and support future pipeline products, addressing growing global demand and pandemic preparedness.

Key Players Analysis

Novartis, Pfizer, and GSK lead the global biopharmaceutical vaccines market, leveraging mRNA and viral vector technologies. Johnson & Johnson focuses on single dose vaccines, while Merck & Co pioneers in HPV prevention. AstraZeneca and Takeda invest in advanced R&D and strategic alliances, driving market growth through innovative pipeline development and addressing unmet medical needs globally.

List of Key Companies:

  1. Novartis
  2. Bayer
  3. AbbVie
  4. AstraZeneca
  5. Takeda
  6. Johnson & Johnson
  7. Merck & Co
  8. Pfizer
  9. GSK
  10. Roche
  11. Moderna
  12. Valneva
  13. Regeneron Pharmaceuticals
  14. BioNTech
  15. Sinovac Biotech
  16. Sanofi

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 78.5 Billion
Forecast Value (2035)USD 155.2 Billion
CAGR (2026-2035)8.7%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Vaccine Type:
    • •Live Attenuated Vaccines
    • •Inactivated Vaccines
    • •Subunit Vaccines
    • •mRNA Vaccines
    • •Viral Vector Vaccines
  • By Disease Type:
    • •Infectious Diseases
    • •Autoimmune Diseases
    • •Cancer
    • •Neurological Disorders
  • By Route of Administration:
    • •Subcutaneous
    • •Intramuscular
    • •Intradermal
    • •Oral
  • By Patient Age Group:
    • •Pediatric
    • •Adult
    • •Geriatric
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Biopharmaceutical Vaccines Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Vaccine Type
5.1.1. Live Attenuated Vaccines
5.1.2. Inactivated Vaccines
5.1.3. Subunit Vaccines
5.1.4. mRNA Vaccines
5.1.5. Viral Vector Vaccines
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
5.2.1. Infectious Diseases
5.2.2. Autoimmune Diseases
5.2.3. Cancer
5.2.4. Neurological Disorders
5.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
5.3.1. Subcutaneous
5.3.2. Intramuscular
5.3.3. Intradermal
5.3.4. Oral
5.4. Market Analysis, Insights and Forecast, 2020-2035, By Patient Age Group
5.4.1. Pediatric
5.4.2. Adult
5.4.3. Geriatric
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Biopharmaceutical Vaccines Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Vaccine Type
6.1.1. Live Attenuated Vaccines
6.1.2. Inactivated Vaccines
6.1.3. Subunit Vaccines
6.1.4. mRNA Vaccines
6.1.5. Viral Vector Vaccines
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
6.2.1. Infectious Diseases
6.2.2. Autoimmune Diseases
6.2.3. Cancer
6.2.4. Neurological Disorders
6.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
6.3.1. Subcutaneous
6.3.2. Intramuscular
6.3.3. Intradermal
6.3.4. Oral
6.4. Market Analysis, Insights and Forecast, 2020-2035, By Patient Age Group
6.4.1. Pediatric
6.4.2. Adult
6.4.3. Geriatric
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Biopharmaceutical Vaccines Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Vaccine Type
7.1.1. Live Attenuated Vaccines
7.1.2. Inactivated Vaccines
7.1.3. Subunit Vaccines
7.1.4. mRNA Vaccines
7.1.5. Viral Vector Vaccines
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
7.2.1. Infectious Diseases
7.2.2. Autoimmune Diseases
7.2.3. Cancer
7.2.4. Neurological Disorders
7.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
7.3.1. Subcutaneous
7.3.2. Intramuscular
7.3.3. Intradermal
7.3.4. Oral
7.4. Market Analysis, Insights and Forecast, 2020-2035, By Patient Age Group
7.4.1. Pediatric
7.4.2. Adult
7.4.3. Geriatric
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Biopharmaceutical Vaccines Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Vaccine Type
8.1.1. Live Attenuated Vaccines
8.1.2. Inactivated Vaccines
8.1.3. Subunit Vaccines
8.1.4. mRNA Vaccines
8.1.5. Viral Vector Vaccines
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
8.2.1. Infectious Diseases
8.2.2. Autoimmune Diseases
8.2.3. Cancer
8.2.4. Neurological Disorders
8.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
8.3.1. Subcutaneous
8.3.2. Intramuscular
8.3.3. Intradermal
8.3.4. Oral
8.4. Market Analysis, Insights and Forecast, 2020-2035, By Patient Age Group
8.4.1. Pediatric
8.4.2. Adult
8.4.3. Geriatric
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Biopharmaceutical Vaccines Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Vaccine Type
9.1.1. Live Attenuated Vaccines
9.1.2. Inactivated Vaccines
9.1.3. Subunit Vaccines
9.1.4. mRNA Vaccines
9.1.5. Viral Vector Vaccines
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
9.2.1. Infectious Diseases
9.2.2. Autoimmune Diseases
9.2.3. Cancer
9.2.4. Neurological Disorders
9.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
9.3.1. Subcutaneous
9.3.2. Intramuscular
9.3.3. Intradermal
9.3.4. Oral
9.4. Market Analysis, Insights and Forecast, 2020-2035, By Patient Age Group
9.4.1. Pediatric
9.4.2. Adult
9.4.3. Geriatric
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Biopharmaceutical Vaccines Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Vaccine Type
10.1.1. Live Attenuated Vaccines
10.1.2. Inactivated Vaccines
10.1.3. Subunit Vaccines
10.1.4. mRNA Vaccines
10.1.5. Viral Vector Vaccines
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
10.2.1. Infectious Diseases
10.2.2. Autoimmune Diseases
10.2.3. Cancer
10.2.4. Neurological Disorders
10.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
10.3.1. Subcutaneous
10.3.2. Intramuscular
10.3.3. Intradermal
10.3.4. Oral
10.4. Market Analysis, Insights and Forecast, 2020-2035, By Patient Age Group
10.4.1. Pediatric
10.4.2. Adult
10.4.3. Geriatric
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Novartis
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Bayer
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. AbbVie
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. AstraZeneca
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Takeda
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Johnson & Johnson
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Merck & Co
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Pfizer
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. GSK
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. Roche
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Moderna
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Valneva
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. Regeneron Pharmaceuticals
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. BioNTech
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. Sinovac Biotech
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis
11.2.16. Sanofi
11.2.16.1. Business Overview
11.2.16.2. Products Offering
11.2.16.3. Financial Insights (Based on Availability)
11.2.16.4. Company Market Share Analysis
11.2.16.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.16.6. Strategy
11.2.16.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035

Table 2: Global Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 3: Global Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 4: Global Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Patient Age Group, 2020-2035

Table 5: Global Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035

Table 7: North America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 8: North America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 9: North America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Patient Age Group, 2020-2035

Table 10: North America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035

Table 12: Europe Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 13: Europe Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 14: Europe Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Patient Age Group, 2020-2035

Table 15: Europe Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035

Table 17: Asia Pacific Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 18: Asia Pacific Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 19: Asia Pacific Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Patient Age Group, 2020-2035

Table 20: Asia Pacific Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035

Table 22: Latin America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 23: Latin America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 24: Latin America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Patient Age Group, 2020-2035

Table 25: Latin America Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035

Table 27: Middle East & Africa Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 28: Middle East & Africa Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 29: Middle East & Africa Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Patient Age Group, 2020-2035

Table 30: Middle East & Africa Biopharmaceutical Vaccines Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;